Market competition
High competition in the probiotic industry could affect market share.
- Materiality
- high
BioGaia
BioGaia AB is a Swedish company specializing in the development, manufacturing, and marketing of probiotic products aimed at enhancing gut, oral, and immune health. With over 35 years of experience in microbiome research, BioGaia is a leader in the probiotic industry, primarily utilizing strains of the lactic acid bacterium Limosilactobacillus reuteri. The company's products are distributed globally through partnerships and direct sales, and its shares are listed on the Nasdaq Stockholm Mid Cap List.
242
6.12
5.21
| % | |
|---|---|
| Gut Health Products | 40% Includes colic drops and chewable tablets for gut health. |
| Oral Health Products | 25% Includes lozenges and tablets for oral health. |
| Immune Health Products | 15% Products designed to support immune health. |
| Licensee Products | 20% Bacterial cultures sold for use in other companies' products. |
BioGaia's customer base is diverse, spanning across nutrition and pharmaceutical companies, healthcare providers, and...
- Nutrition Companiesprimary
Purchase bacterial cultures for integration into their products.
- Pharmaceutical Companiesprimary
Distribute BioGaia's probiotic products globally.
- Direct Consumerssecondary
Buy probiotic supplements for personal health benefits.
- Licenseessecondary
Incorporate BioGaia's strains into their own products.
BioGaia operates in over 100 countries, with direct sales subsidiaries in nine key markets including Sweden, Finland,...
- •Operates in over 100 countries with a strong presence in North America and APAC.
- •Direct sales subsidiaries in nine countries including Sweden and the USA.
- •Holds patents in all major markets for proprietary strains and packaging.
- •Strong demand in North America, particularly in the USA and Canada.
- •APAC region shows robust growth driven by online sales and marketing.
BioGaia's strategic priorities focus on expanding its brand presence and increasing direct sales...
01
Expand direct salesmedium-term
To increase market penetration and control distribution.
02
Focus on adult health segmentshort-term
To capitalize on growing demand for adult probiotics.
03
Enhance online salesmedium-term
To reach a wider consumer base and increase sales.
BioGaia faces several risks, including market competition, regulatory changes, and currency fluctuations...
Currency fluctuations
Fluctuations in SEK can affect profitability.
- Materiality
- high
Regulatory changes
Changes in health standards could impact product approvals.
- Materiality
- medium
Revenue recognition
Currency translation adjustments
Fair value measurements
Cloetta
CLA-B.ST · Consumer Staples
Cloetta is a prominent confectionery company in Northern Europe, known for its strong local brands in the confectionery and nuts segments.
BIOMERICA INC
BMRA · In Vitro & In Vivo Diagnostic Substances
Niagen Bioscience, Inc.
NAGE · Medicinal Chemicals & Botanical Products
BioAge Labs, Inc.
BIOA · Pharmaceutical Preparations
Atria Oyj
ATRAV.HE · Packaged Foods
Atria is a leading Nordic food company specializing in the production and sale of fresh and processed meat products.
BIOCRYST PHARMACEUTICALS INC
BCRX · Biological Products, (No Diagnostic Substances)
Biocryst Pharmaceuticals is a U.S.-based biotechnology company focused on rare diseases, with its core commercial product ORLADEYO for hereditary angioedema (HAE).
: 11/08/2026